Mrs Sonia Fox BSc

Institute of Cancer and Genomic Sciences
Haematology – TAP Trials Team Leader

Contact details

Telephone
+44 (0)121 415 9181
Fax
+44 (0)121 414 6061
Email
s.fox.2@bham.ac.uk
Address
Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
The University of Birmingham
Edgbaston
Birmingham B15 2TT

Sonia Fox is the Haematology and Trials Acceleration Programme Team Leader at the at the Cancer
Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

Qualifications

BSc Biological Sciences, Honours in Pharmacology with Industrial Experience, University of Edinburgh, 2007

Biography

Sonia Fox graduated with a Biological Sciences, Honours in Pharmacology with Industrial Experience Degree in 2007.

She joined the BCTU at the University of Birmingham as a Trial Administrator in 2007. She was promoted to Trial Coordinator at the CRCTU in 2009 and subsequently to Senior Trial Coordinator in 2011. Her experience has been predominately in early phase trials of haematological malignancies, with a particular interest in myeloid studies and novel agents.

She was appointed to Haematology Trial Management Team Leader for the Trials Acceleration Programme (TAP) at the CRCTU in 2017.

Research

Sonia Fox has contributed to the design, set-up and/or management of the following trials:

  • STELLAR (Richter's Syndrome)
  • TAMARIN (Myeloproliferative Neoplasms)
  • AZTEC (Graft versus Host Disease)
  • PHAZAR (Accelerated phase Myeloproliferative Neoplasms)
  • TIER (CNS Lymphoma)
  • RomiCar (T-cell lymphoma)
  • ELASTIC (Myelodysplastic syndrome)
  • CyCLLe (CLL)
  • MAJIC (Myeloproliferative Neoplasms)
  • RAvVA (Acute Myeloid Leukaemia/Myelodysplastic syndrome)
  • ROMAZA (Acute Myeloid Leukaemia)
  • De-Iron (Myelodysplastic syndrome)
  • BaP (MDS/NHL/CLL)
  • TACE-2 (Hepatocellular carcinoma)

Publications

Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Aliman, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa R; McMullin, MF. (2017). “Ruxolitinib versus Best Available Therapy for ET intolerant or resistant to Hydroxycarbamide in a Randomized trial”. Blood, 130:1889-1897